Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2023 Earnings Call Transcript
Capricor Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.23. Capricor Therapeutics, Inc.
Capricor Therapeutics Inc. (CAPR)
Market is closed
News
- Displaying 7
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, this is the conference operator. Welcome to Capricor First Quarter 2023 Financial Results and Corporate Update Call.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to Capricor Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode.
Hedge Funds Are Betting On Capricor Therapeutics, Inc. (CAPR)
Is Capricor Therapeutics, Inc.
Here is What Hedge Funds Think About Capricor Therapeutics, Inc. (CAPR)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Billionaire Hedge Funds
